Last reviewed · How we verify

Rosuvastatin, Olmesartan Medoxomil

Daewoong Pharmaceutical Co. LTD. · Phase 2 active Small molecule

Rosuvastatin, Olmesartan Medoxomil is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 2 development.

At a glance

Generic nameRosuvastatin, Olmesartan Medoxomil
SponsorDaewoong Pharmaceutical Co. LTD.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rosuvastatin, Olmesartan Medoxomil

What is Rosuvastatin, Olmesartan Medoxomil?

Rosuvastatin, Olmesartan Medoxomil is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD..

Who makes Rosuvastatin, Olmesartan Medoxomil?

Rosuvastatin, Olmesartan Medoxomil is developed by Daewoong Pharmaceutical Co. LTD. (see full Daewoong Pharmaceutical Co. LTD. pipeline at /company/daewoong-pharmaceutical-co-ltd).

What development phase is Rosuvastatin, Olmesartan Medoxomil in?

Rosuvastatin, Olmesartan Medoxomil is in Phase 2.

Related